Carlsbad, CA – According to filings with the U.S. Securities and Exchange Commission, Design Therapeutics is raising $125,000,063.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Joao Siffert played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Design Therapeutics

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

To learn more about Design Therapeutics, visit http://www.designtx.com/

Contact:
Joao Siffert, President and Chief Executive Officer
858-293-4900
https://www.linkedin.com/in/joao-siffert-4b14b64/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved